Administration Core

行政核心

• 批准号: 10540774
• 负责人: CLARE M TEMPANY
• 金额: $ 26.06万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-01-06 至 2025-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10540774
• 关键词: Acute; Advisory Committees; Algorithms; Articulation; Attention; Beds; Biomedical Research; Cancer Biology; Clinical; Collaborations; Collection; Communication; Communities; Consultations; Data; Data Set; Dedications; Development; Devices; Early Diagnosis; Ensure; Equipment; Event; Evolution; Feedback; Funding; Geographic Distribution; Geography; Goals; Grant; Group Meetings; Guidelines; Healthcare; Heterogeneity; Human; Image; Imaging Device; Immunotherapy; Information Retrieval; Investigation; Knowledge; Leadership; Lesion; Manuscripts; Medical; Mentors; Mission; Monitor; Nanotechnology; Neoplasm Metastasis; Operative Surgical Procedures; Participant; Patient Care; Patients; Pattern; Phase; Policies; Procedures; Publications; Recurrence; Research; Research Activity; Research Design; Research Personnel; Resistance; Resources; Services; Strategic Planning; Structure; Technology; Testing; Time; Tissues; United States National Institutes of Health; Vision; Work; big-data science; biomedical resource; cancer care; cancer heterogeneity; cancer imaging; care providers; data curation; data integration; deep learning; digital; experience; image guided; image guided therapy; imaging facilities; imaging modality; innovation; interest; meetings; neoplastic; new technology; novel; operation; personalized cancer therapy; personalized medicine; precision medicine; programs; research study; response; shared decision making; skills; sound; technology research and development; tumor; Acute; Advisory Committees; Algorithms; Articulation; Attention; Beds; Biomedical Research; Cancer Biology; Clinical; Collaborations; Collection; Communication; Communities; Consultations; Data; Data Set; Dedications; Development; Devices; Early Diagnosis; Ensure; Equipment; Event; Evolution; Feedback; Funding; Geographic Distribution; Geography; Goals; Grant; Group Meetings; Guidelines; Healthcare; Heterogeneity; Human; Image; Imaging Device; Immunotherapy; Information Retrieval; Investigation; Knowledge; Leadership; Lesion; Manuscripts; Medical; Mentors; Mission; Monitor; Nanotechnology; Neoplasm Metastasis; Operative Surgical Procedures; Participant; Patient Care; Patients; Pattern; Phase; Policies; Procedures; Publications; Recurrence; Research; Research Activity; Research Design; Research Personnel; Resistance; Resources; Services; Strategic Planning; Structure; Technology; Testing; Time; Tissues; United States National Institutes of Health; Vision; Work; big-data science; biomedical resource; cancer care; cancer heterogeneity; cancer imaging; care providers; data curation; data integration; deep learning; digital; experience; image guided; image guided therapy; imaging facilities; imaging modality; innovation; interest; meetings; neoplastic; new technology; novel; operation; personalized cancer therapy; personalized medicine; precision medicine; programs; research study; response; shared decision making; skills; sound; technology research and development; tumor

The intersection of healthcare and biomedical research is at an inflection point with the convergence of cancer biology combined with new personalized therapies, the digital revolution, nanotechnology, big data science, and precision or personalized medicine. There is a wealth of meaningful information and knowledge that could be extracted from imaging data, but is currently not fully accessible by clinicians and hence cannot be optimally utilized for patient care, procedures or surgery. Medical care providers are constantly inundated with increasing amounts of patient data (both relevant and not) which are increasing in complexity. Cancer care exemplifies the current clinical challenges which include early detection, accurate distinction of pre-neoplastic and neoplastic lesions, determining infiltrative tumor margins during surgical treatment, tracking tumor evolution and potential acquired resistance to treatments over time, and prediction of tumor aggressiveness, metastasis pattern, and recurrence. Major strides have been made in the personalization of cancer therapies such as immunotherapy but the availability of specific, relevant, and timely medical data and information is of critical importance to realizing the full potential of precision medicine. Nowhere is this more acutely evident than during medical/surgical interventions in the operating and procedure rooms. Novel methods of imaging cancer to investigate the microstructure and inherent heterogeneity, image guidance, data integration, information extraction, and knowledge transfer are critical to inform and enable clinicians to fully leverage the information available, especially before, during and after invasive procedures. We are excited to propose this revised P41 biomedical resource center (BTRC) called Advanced Technologies for NCIGT or AT-NCIGT with 3 TRDs, 10 CP’s & 10 SPs. The 3 components, which we will investigate and develop new technology for are: Imaging Cancer heterogenity, Deep Learning and Intraoperative devices for image guided therapy. The BTRC will be organized with senior level experienced team led by the PI, assisted by TRD PI’s and others. They will support all research activities, ensure CP/SP support and review and mentor junior investigators and trainees. The overall goal of this proposal is to investigate, develop, and disseminate novel advanced technologies such as new MR sequences for tissue characterization-Imaging Cancer Heterogeneity (TR&D 1); analyze them and make them available through state-of-the- art algorithmic and data curation approaches (Deep Learning TR&D 2); and development of a set of comprehensive intraoperative planning, guidance and monitoring technologies and devices ( Intraoperative devices for image guided therapy TR&D 3). We will disseminate all innovations and specific deliverables to the CPs and SPs through the established mechanisms of the National Center for Image Guided Therapy (NCIGT), which continues to be dedicated to the investigation of the technical needs of IGT.

医疗保健和生物医学研究的交集处于与 癌症生物学结合新的个性化疗法，数字革命，纳米技术，大数据 科学，精度或个性化医学。有很多有意义的信息， 可以从成像数据中提取的知识，但目前临床医生和 因此，不能最佳地用于患者护理，程序或手术。医疗服务提供者是 不断增加的患者数据（相关和非相关）不断淹没 复杂性。癌症护理体现了当前的临床挑战，包括早期检测， 准确区分肿瘤前和肿瘤病变，确定浸润性肿瘤边缘 手术治疗，跟踪肿瘤的演变以及对治疗的潜在抗药性 时间和肿瘤侵袭性，转移模式和复发的预测。大步很大 是在癌症疗法的个性化中进行的，例如免疫疗法，但可用性 具体，相关且及时的医学数据和信息对于实现完整 精确医学的潜力。没有什么比医学/外科手术更敏锐的证据 操作和过程室的干预措施。成像癌的新方法研究 微观结构和继承异质性，图像指导，数据集成，信息提取和 知识转移对于告知和使临床医生能够充分利用可用信息至关重要， 尤其是在侵入性程序之前，之中和之后。我们很高兴提出此修订后的P41 生物医学资源中心（BTRC）称为NCIGT或AT-NCIGT的高级技术，带有3 trds， 10 cp和10 sps。我们将研究和开发新技术的3个组件是： 成像癌症异质性，深度学习和用于图像指导疗法的术中装置。 BTRC将与由PI领导的高级经验团队一起组织，在TRD PI和 其他的。他们将支持所有研究活动，确保CP/SP支持和审查以及精神少年 调查人员和学员。该建议的总体目标是调查，发展和传播 新型的高级技术，例如新的MR序列，用于组织表征模仿癌症 异质性（TR＆D 1）;分析它们并通过最先进的算法和 数据策划方法（深度学习TR＆D 2）；以及一组综合的发展 术中计划，指导和监测技术和设备（术中设备 图像指导疗法TR＆D 3）。我们将向CPS传播所有创新和特定的可交付成果 和SPS通过国家图像指导疗法中心的既定机制 （NCIGT），它继续致力于IGT技术需求的投资。